ME-344

ME-344 is a mitochondrial Heme oxygenase 1 (HO-1) inhibitor. ME-344 specifically binds and alters HO-1 structure, and increases HO-1 translocation from the rough endoplasmic reticulum to mitochondria, but only in drug-sensitive cells (such as H460 and SHP-77 cells) . ME-344 decreases mitochondrial ATP production and induces ROS, with subsequent disruption of redox homeostasis and mitochondrial function. ME-344 has significant antitumor activity, and can be used for cancers like breast cancer research[1].

Product Specifications

CAS Number

[1374524-68-1]

UNSPSC

12352005

Target

Heme Oxygenase (HO) ; Mitochondrial Metabolism; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/me-344.html

Purity

98.12

Solubility

10 mM in DMSO

Smiles

OC1=CC=C2[C@H](C3=CC=C(O)C=C3)[C@H](C4=CC=C(O)C=C4)COC2=C1C

Molecular Formula

C22H20O4

Molecular Weight

348.39

References & Citations

[1]Miguel Quintela-Fandino, et al. Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer. Clin Cancer Res. 2020, 26, 1.|[2]Zhang L, et al. Isoflavone ME-344 Disrupts Redox Homeostasis and Mitochondrial Function by Targeting Heme Oxygenase 1. Cancer Res. 2019 Aug 15;79 (16) :4072-4085.